📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
In 2024, Novartis completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Novartis has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Novartis’s data sources below and access millions more through our Disclosure Search.
In 2024, the total operational greenhouse gas (GHG) emissions ofNovartis amounted to407,400metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Novartisdecreased by 8.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Novartis were 207,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Since 2019, Novartis's Scope 1 emissions have decreased by 57.28%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year(2023), Novartis's Scope 1 emissions decreased by 17.56%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Novartis reported Scope 2 greenhouse gas (GHG) emissions of 30,000 tCOâ‚‚e using the market-based method and 200,400 tCOâ‚‚e using the location-based method.a
Since 2019, Novartis's Scope 2 greenhouse gas (GHG) emissions (Location-Based)have decreased by 56.14%, reflecting a declining long-term trend in Scope 2 emissions over time.ac
Compared to the previous year(2023), Novartis's Scope 2 emissions(Location-Based) have remained relatively stable, indicating that Novartis's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Novartis reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Novartis reported 4,350,300 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Novartis includes a breakdown across 12of the 15 Scope 3 categories defined by the GHG Protocol,matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Novartis reported total Scope 3 emissions of 4,350,300 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Approximately 95.77%of these emissions originated from upstream activities such as purchased goods and capital goods, while 4.23%came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Novartis's Scope 3 emissionshave decreased by 28.1%, reflecting a declining long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Novartis's Scope 3 emissions remained relatively stable, indicating that Novartis's emissions have plateaued with no significant change in its value chain footprint.a
In 2024, Novartis reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Novartis's Scope 3 emissions were:a
In 2024, Novartis reported Scope 1 greenhouse gas (GHG) emissions of 207,000 tCOâ‚‚e and total revenues of USD 41,706 millions. This translates into an emissions intensity of 4.96 tCOâ‚‚e per millions USD.a
In 2024, Novartis reported a Scope 1 emissions intensity of 4.96 tCOâ‚‚e per millions USD. Compared to the peer group median of 5.34, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Novartis ranked 11 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
Novartis is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Novartis reported a total carbon footprint of 4,757,700 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.22% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Novartis's total carbon footprint was Scope 3 emissions, accounting for 91.44% of the company's total carbon footprint, followed by Scope 1 emissions at 4.35%.a